Literature DB >> 17908238

Cerebral clearance of human amyloid-beta peptide (1-40) across the blood-brain barrier is reduced by self-aggregation and formation of low-density lipoprotein receptor-related protein-1 ligand complexes.

Shingo Ito1, Sumio Ohtsuki, Junichi Kamiie, Yasuko Nezu, Tetsuya Terasaki.   

Abstract

Soluble amyloid-beta peptide (Abeta) exists in the form of monomers and oligomers, and as complexes with Abeta-binding molecules, such as low-density lipoprotein receptor-related protein-1 (LRP-1) ligands. The present study investigated the effect of self-aggregation and LRP-1 ligands on the elimination of human Abeta(1-40) [hAbeta(1-40)] from the rat brain across the blood-brain barrier. Incubation of [(125)I]hAbeta(1-40) monomer resulted in time-dependent and temperature-dependent dimer formation, and the apparent elimination rate of [(125)I]hAbeta(1-40) dimer was significantly decreased by 92.7% compared with that of [(125)I]hAbeta(1-40) monomer. Pre-incubation with LRP-1 ligands, such as activated alpha2-macroglobulin (alpha2M), apolipoprotein E2 (apoE2), apoE3, apoE4, and lactoferrin, reduced the elimination of [(125)I]hAbeta(1-40). By contrast, pre-administration of the same concentration of these molecules in the rat brain did not significantly inhibit [(125)I]hAbeta(1-40) monomer elimination. Purified [(125)I]hAbeta(1-40)/activated alpha2M complex and [(125)I]activated alpha2M were not significantly eliminated from the rat brain up to 60 min. MEF-1 cells, which have LRP-1-mediated endocytosis, exhibited uptake of [(125)I]activated alpha2M, and enhancement of [(125)I]hAbeta(1-40) uptake upon pre-incubation with apoE, suggesting that [(125)I]activated alpha2M and [(125)I]hAbeta(1-40)/apoE complex function as LRP-1 ligands. These findings indicate that dimerization and LRP-1-ligand complex formation prevent the elimination of hAbeta(1-40) from the brain across the blood-brain barrier.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17908238     DOI: 10.1111/j.1471-4159.2007.04938.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  36 in total

1.  Oxidative modification to LDL receptor-related protein 1 in hippocampus from subjects with Alzheimer disease: implications for Aβ accumulation in AD brain.

Authors:  Joshua B Owen; Rukhsana Sultana; Christopher D Aluise; Michelle A Erickson; Tulin O Price; Guojun Bu; William A Banks; D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2010-10-07       Impact factor: 7.376

Review 2.  Alzheimer's disease: pathophysiology and applications of magnetic nanoparticles as MRI theranostic agents.

Authors:  Houshang Amiri; Kolsoum Saeidi; Parvin Borhani; Arash Manafirad; Mahdi Ghavami; Valerio Zerbi
Journal:  ACS Chem Neurosci       Date:  2013-09-26       Impact factor: 4.418

3.  Alzheimer's disease drug development and the problem of the blood-brain barrier.

Authors:  William M Pardridge
Journal:  Alzheimers Dement       Date:  2009-09       Impact factor: 21.566

Review 4.  Mouse models of neurological disorders: a view from the blood-brain barrier.

Authors:  William A Banks
Journal:  Biochim Biophys Acta       Date:  2009-10-29

5.  Atrial natriuretic peptide is eliminated from the brain by natriuretic peptide receptor-C-mediated brain-to-blood efflux transport at the blood-brain barrier.

Authors:  Shingo Ito; Sumio Ohtsuki; Yuki Katsukura; Miho Funaki; Yusuke Koitabashi; Akihiko Sugino; Sho Murata; Tetsuya Terasaki
Journal:  J Cereb Blood Flow Metab       Date:  2010-07-14       Impact factor: 6.200

Review 6.  Low-density lipoprotein receptor-related protein 1: a physiological Aβ homeostatic mechanism with multiple therapeutic opportunities.

Authors:  Abhay P Sagare; Rashid Deane; Berislav V Zlokovic
Journal:  Pharmacol Ther       Date:  2012-07-20       Impact factor: 12.310

7.  Decreased levels of PSD95 and two associated proteins and increased levels of BCl2 and caspase 3 in hippocampus from subjects with amnestic mild cognitive impairment: Insights into their potential roles for loss of synapses and memory, accumulation of Abeta, and neurodegeneration in a prodromal stage of Alzheimer's disease.

Authors:  Rukhsana Sultana; William A Banks; D Allan Butterfield
Journal:  J Neurosci Res       Date:  2010-02-15       Impact factor: 4.164

8.  Endothelial LRP1 transports amyloid-β(1-42) across the blood-brain barrier.

Authors:  Steffen E Storck; Sabrina Meister; Julius Nahrath; Julius N Meißner; Nils Schubert; Alessandro Di Spiezio; Sandra Baches; Roosmarijn E Vandenbroucke; Yvonne Bouter; Ingrid Prikulis; Carsten Korth; Sascha Weggen; Axel Heimann; Markus Schwaninger; Thomas A Bayer; Claus U Pietrzik
Journal:  J Clin Invest       Date:  2015-11-30       Impact factor: 14.808

9.  Central and peripheral administration of antisense oligonucleotide targeting amyloid-β protein precursor improves learning and memory and reduces neuroinflammatory cytokines in Tg2576 (AβPPswe) mice.

Authors:  Susan A Farr; Michelle A Erickson; Michael L Niehoff; William A Banks; John E Morley
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

10.  Increased expression of cholesterol transporter ABCA1 is highly correlated with severity of dementia in AD hippocampus.

Authors:  Afia Akram; James Schmeidler; Pavel Katsel; Patrick R Hof; Vahram Haroutunian
Journal:  Brain Res       Date:  2010-01-14       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.